CBIO Q2 2022 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$75,000+52716.9% YoY

Gross Profit

$75,000100.0% margin

Operating Income

-$13M-17804.2% margin

Net Income

-$13M-17690.1% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$963,758

Balance Sheet

Total Assets

$65M

Total Liabilities

$9M

Stockholders' Equity

$56M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75,000	$142	+52716.9%
Gross Profit	$75,000	$142	+52716.9%
Operating Income	-$13M	-$14M	+7.3%
Net Income	-$13M	-$14M	+7.9%